Prevalences of hyperuricemia and electrolyte abnormalities in patients with chronic kidney disease in Japan: A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB).
Adolescent
Adult
Aged
Aged, 80 and over
Cross-Sectional Studies
Databases, Factual
Electrolytes
/ blood
Female
Glomerular Filtration Rate
Hospitals, University
Humans
Hyperuricemia
/ complications
Japan
/ epidemiology
Male
Middle Aged
Prevalence
Renal Insufficiency, Chronic
/ complications
Severity of Illness Index
Uric Acid
/ blood
Young Adult
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
26
07
2020
accepted:
24
09
2020
entrez:
15
10
2020
pubmed:
16
10
2020
medline:
15
12
2020
Statut:
epublish
Résumé
The Japan Chronic Kidney Disease Database (J-CKD-DB) is a nationwide clinical database of patients with chronic kidney disease (CKD) based on electronic health records. The objective of this study was to assess the prevalences of hyperuricemia and electrolyte abnormalities in Japanese patients with CKD. In total, 35,508 adult outpatients with estimated glomerular filtration rates of 5-60 ml/min/1.73 m2 in seven university hospitals were included this analysis. The proportions of patients with CKD stages G3b, G4, and G5 were 23.5%, 7.6%, and 3.1%, respectively. Logistic regression analysis showed that prevalence of hyperuricemia was associated with CKD stages G3b (adjusted odds ratio [95% confidence interval]: 2.12 [1.90-2.37]), G4 (4.57 [3.92-5.32]), and G5 (2.25 [1.80-2.80]). The respective prevalences of hyponatremia, hypercalcemia, hyperphosphatemia, and narrower difference between serum sodium and chloride concentrations were elevated in patients with CKD stages G3b, G4, and G5, compared with those prevalences in patients with CKD stage G3a. The prevalences of hyperkalemia were 8.3% and 11.6% in patients with CKD stages G4 and G5, respectively. In patients with CKD stage G5, the proportions of patients with optimal ranges of serum uric acid, potassium, corrected calcium, and phosphate were 49.6%, 73.5%, 81.9%, and 56.1%, respectively. We determined the prevalences of hyperuricemia and electrolyte abnormalities in Japanese patients with CKD using data from a nationwide cohort study.
Sections du résumé
BACKGROUND
The Japan Chronic Kidney Disease Database (J-CKD-DB) is a nationwide clinical database of patients with chronic kidney disease (CKD) based on electronic health records. The objective of this study was to assess the prevalences of hyperuricemia and electrolyte abnormalities in Japanese patients with CKD.
METHODS
In total, 35,508 adult outpatients with estimated glomerular filtration rates of 5-60 ml/min/1.73 m2 in seven university hospitals were included this analysis. The proportions of patients with CKD stages G3b, G4, and G5 were 23.5%, 7.6%, and 3.1%, respectively.
RESULTS
Logistic regression analysis showed that prevalence of hyperuricemia was associated with CKD stages G3b (adjusted odds ratio [95% confidence interval]: 2.12 [1.90-2.37]), G4 (4.57 [3.92-5.32]), and G5 (2.25 [1.80-2.80]). The respective prevalences of hyponatremia, hypercalcemia, hyperphosphatemia, and narrower difference between serum sodium and chloride concentrations were elevated in patients with CKD stages G3b, G4, and G5, compared with those prevalences in patients with CKD stage G3a. The prevalences of hyperkalemia were 8.3% and 11.6% in patients with CKD stages G4 and G5, respectively. In patients with CKD stage G5, the proportions of patients with optimal ranges of serum uric acid, potassium, corrected calcium, and phosphate were 49.6%, 73.5%, 81.9%, and 56.1%, respectively.
CONCLUSIONS
We determined the prevalences of hyperuricemia and electrolyte abnormalities in Japanese patients with CKD using data from a nationwide cohort study.
Identifiants
pubmed: 33057377
doi: 10.1371/journal.pone.0240402
pii: PONE-D-20-23242
pmc: PMC7561156
doi:
Substances chimiques
Electrolytes
0
Uric Acid
268B43MJ25
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0240402Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
Nephrol Dial Transplant. 2018 Aug 1;33(8):1373-1379
pubmed: 29045728
Clin Exp Nephrol. 2019 Feb;23(2):215-222
pubmed: 30168046
Clin Exp Nephrol. 2017 Feb;21(1):104-111
pubmed: 27039905
Clin Exp Nephrol. 2009 Dec;13(6):621-30
pubmed: 19513802
Ther Apher Dial. 2013 Jun;17(3):247-88
pubmed: 23735142
Am J Kidney Dis. 2017 May;69(5):707-708
pubmed: 28285873
Int Urol Nephrol. 2018 Oct;50(10):1871-1877
pubmed: 29882003
JMIR Med Inform. 2016 Apr 05;4(2):e12
pubmed: 27050304
J Am Soc Nephrol. 2009 Sep;20(9):2075-84
pubmed: 19608703
Kidney Int Suppl (2011). 2013 Jan;3(1):19-62
pubmed: 25018975
PLoS One. 2020 Jul 20;15(7):e0236132
pubmed: 32687544
Int J Nephrol Renovasc Dis. 2013;6:1-13
pubmed: 23319870
J Clin Pharmacol. 1973 Aug-Sep;13(8):357-64
pubmed: 4579972
Br Med J. 1973 Dec 15;4(5893):643-6
pubmed: 4758544
Kidney Int. 2005 Jun;67(6):2089-100
pubmed: 15882252
J Atheroscler Thromb. 2017 Jun 1;24(6):630-642
pubmed: 27784849
Adv Chronic Kidney Dis. 2017 Sep;24(5):315-318
pubmed: 29031358
Am J Kidney Dis. 2013 Oct;62(4):670-8
pubmed: 23489677
Methods Inf Med. 2011;50(2):131-9
pubmed: 21206962
Kidney Int. 2008 Jul;74(1):108-14
pubmed: 18432185
Nephrol Dial Transplant. 2007 Oct;22(10):2909-16
pubmed: 17517792
Nucleosides Nucleotides Nucleic Acids. 2011 Dec;30(12):1039-44
pubmed: 22132954
Clin J Am Soc Nephrol. 2010 May;5(5):762-9
pubmed: 20203167
Diabet Med. 2010 Sep;27(9):1017-23
pubmed: 20722675
Diabetol Int. 2017 Jun 27;8(4):375-382
pubmed: 30603343
Sci Rep. 2017 Sep 14;7(1):11530
pubmed: 28912532
Int Urol Nephrol. 2019 Jun;51(6):1013-1018
pubmed: 31020628
Nucleosides Nucleotides Nucleic Acids. 2011 Dec;30(12):1018-29
pubmed: 22132951
Am J Nephrol. 2015;41(6):456-63
pubmed: 26228532
Nephrol Dial Transplant. 2017 Apr 1;32(suppl_2):ii142-ii150
pubmed: 28201668
Sci Rep. 2020 Apr 30;10(1):7351
pubmed: 32355258
Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266
pubmed: 11904577
Am J Kidney Dis. 2009 Jun;53(6):982-92
pubmed: 19339088
Arch Intern Med. 2009 Jun 22;169(12):1156-62
pubmed: 19546417
Kidney Int Rep. 2019 May 30;4(9):1248-1260
pubmed: 31517144
J Am Soc Nephrol. 2005 Feb;16(2):520-8
pubmed: 15615819
BMC Public Health. 2008 Apr 11;8:117
pubmed: 18405348
Am J Kidney Dis. 2019 Feb;73(2):206-217
pubmed: 30348535
Circulation. 2003 Oct 28;108(17):2154-69
pubmed: 14581387
Am J Nephrol. 2014;39(4):288-96
pubmed: 24714513